Departmental Papers (Dental)

Document Type

Journal Article

Date of this Version


Publication Source

Tissue Engineering - Part A.





Start Page


Last Page





A central challenge in tissue engineering is obtaining a suitable cell type with a capable delivery vehicle to replace or repair damaged or diseased tissues with tissue mimics. Notably, for skeletal muscle tissue engineering, given the inadequate availability and regenerative capability of endogenous myogenic progenitor cells as well as the tumorigenic risks presented by the currently available pluri- and multipotent stem cells, seeking a safe regenerative cell source is urgently demanded. To conquer this problem, we previously established a novel reprogramming technology that can generate multipotent cells from dermal fibroblasts using a single protein, fibromodulin (FMOD). The yield FMOD-reprogrammed (FReP) cells exhibit exceeding myogenic capability without tumorigenic risk, making them a promising and safe cell source for skeletal muscle establishment. In addition to using the optimal cell for implantation, it is equally essential to maintain cellular localization and retention in the recipient tissue environment for critical-sized muscle tissue establishment. In this study, we demonstrate that the photopolymerizable methacrylated glycol chitosan (MeGC)/type I collagen (ColI)hydrogel provides a desirable microenvironment for encapsulated FReP cell survival, spreading, extension, and formation of myotubes in the hydrogel three-dimensionally in vitro, without undesired osteogenic, chondrogenic, or tenogenic differentiation. Furthermore, gene profiling revealed a paired box 7 (PAX7) / myogenic factor 5 (MYF5) / myogenic determination 1 (MYOD1) / myogenin (MYOG) / myosin cassette elevation in the encapsulated FReP cells during myogenic differentiation, which is similar to that of the predominant driver of endogenous skeletal muscle regeneration, satellite cells. These findings constitute the evidence that the FReP cell-MeGC/ColI-hydrogel construct is a promising tissue engineering mimic for skeletal muscle generation in vitro, and thus possesses the extraordinary potential for further in vivo validation. © 2020 Mary Ann Liebert Inc.. All rights reserved.


Fibromodulin, Fibromodulin-reprogrammed cells, Myogenesis, Photopolymerizable hydrogel, Cell Differentiation, Cells, Cultured, Fibromodulin, Humans, Hydrogels, Muscle Development, Muscle, Skeletal, Regeneration, Satellite Cells, Skeletal Muscle, chitosan derivative, collagen type 1, fibromodulin, hydrogel, methacrylated glycol chitosan, MyoD1 protein, myogenic factor 5, myogenin, myosin, myosin heavy chain, myosin heavy chain 1, myosin heavy chain 2, transcription factor PAX7, unclassified drug, apoptosis, BJ [Human fibroblast] cell line, bone development, cell differentiation, cell encapsulation, cell reprogramming technique, cell spreading, cell survival, cell viability, cellular distribution, chondrogenesis, controlled study, evidence based practice, gene expression profiling, graft recipient, histogenesis, human, human cell, immunofluorescence, in vitro study, male, microenvironment, muscle development, muscle regeneration, muscle tissue, myotube, Note, priority journal, skeletal muscle, skeletal muscle cell, skeletal muscle satellite cell, tenogenesis, tissue engineering, cell culture, hydrogel, muscle development, regeneration, skeletal muscle, skeletal muscle satellite cell

Additional Files

supp_table1.docx (52 kB)
supp_fig1-table2.pdf (116 kB)



Date Posted: 10 February 2023

This document has been peer reviewed.